Trial site
MEDITRIAL s.r.o.
Jindrichuv Hradec III, South Bohemian Region 377 01, CzechiaEU-13 widening countryNot linked to an institution yet
- 12running trials
- 19closed trials
The trials here
What the 31 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 211 trials
- Phase 2/31 trial
- Status
- Completed19 trials
- Recruiting6 trials
- Active, not recruiting4 trials
- Not yet recruiting2 trials
- Lead sponsor
- AstraZeneca6 trials
- Chiesi Farmaceutici S.p.A.6 trials
- Sanofi4 trials
- GlaxoSmithKline3 trials
- Pfizer2 trials
- and 9 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source
Completed
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045· Phase 2· Amgen Inc.· Source
Completed
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419· Phase 2· AstraZeneca· Source
Completed
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391· Phase 2· Sanofi· Source
Completed
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· Phase 3· Sanofi· Source
Completed
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy
2022-502854-16-00· Phase 2· Rapt Therapeutics Inc.· Source
Completed
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy
2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Completed
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
NCT05398263· Phase 3· AstraZeneca AB· Source
Completed
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
NCT05243680· Phase 3· GlaxoSmithKline· Source
Completed
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)
2023-507093-40-00· Phase 2· Genentech Inc.· Source
Completed
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT05166889· Phase 3· AstraZeneca· Source
Completed
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy
NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
NCT04609904· Phase 3· AstraZeneca· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04751487· Phase 3· Sanofi· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04701983· Phase 3· Sanofi· Source
Completed
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
NCT04053634· Phase 3· AstraZeneca· Source
Report an error